Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.67 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.56 |
| ▸ | RELA | Q04206 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Psi-Tectorigenin SCHEMBL29783038 | 1.00 | ALDH1A1 (0.70) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL17938763 | 0.91 | ALDH1A1 (0.82) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL12073752 | 0.90 | ALDH1A1 (0.65) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL20524674 | 0.88 | ALDH1A1 (0.63) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL29664054 | 0.88 | ALDH1A1 (0.63) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL6338407 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL29706518 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL28347244 | 0.83 | EGFR (0.62) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL15853599 | 0.82 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4MAPK1EGFR | |
| SCHEMBL572094 | 0.82 | ALDH1A1 (0.74) | ALDH1A1MAPTCYP3A4MAPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20200405797-A1 | TRANSMUCOSAL DELIVERY DEVICE AND METHOD OF MANUFACTURING SAME | NANOSTRIPS, INC. (US) | 2020-12-31 | — | — | US | claimed |
| CN-1986556-A | Blackberry lily isoflavone compound and its application in medical field | UNIV PLA 2ND MILITARY MEDICAL (CN) | 2007-06-27 | — | — | CN | claimed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| CN-113582957-B | Preparation method of isobelamcanda rhizome aglycone | 四川省中医药科学院 | 2023-04-07 | — | — | CN | disclosed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11584769-B2 | Diterpene glycosides, compositions and purification methods | THE COCA-COLA COMPANY (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022232635-A1 | CELLULAR COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| EP-1415156-A2 | METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF THE MULTIPLE PROTEINS IN SINGLE CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003067210-A9 | METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF THE MULTIPLE PROTEINS IN SINGLE CELLS | UNIV LELAND STANFORD JUNIOR (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003067210-A2 | METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF THE MULTIPLE PROTEINS IN SINGLE CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0809493-B1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | US HEALTH (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1161540-A1 | GENETIC MANIPULATION OF ISOFLAVONOIDS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000053771-A1 | GENETIC MANIPULATION OF ISOFLAVONOIDS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1997043643-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA INDUCED MUCIN PRODUCTION: COMPOSITIONS AND TREATMENTS FOR CYSTIC FIBROSIS PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584769-B2 | Diterpene glycosides, compositions and purification methods | DDOST, GYPA, DAD1 | ALDH1A1 4149/4885MAPT 4592/4885CYP3A4 920/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ALDH1A1 2722/4885MAPT 3926/4885CYP3A4 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.